Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) EBITDA Margin: 2024-2025

Historic EBITDA Margin for Prime Medicine (PRME) over the last 2 years, with Sep 2025 value amounting to -4,125.63%.

  • Prime Medicine's EBITDA Margin rose 2095858.00% to -4,125.63% in Q3 2025 from the same period last year, while for Sep 2025 it was -3,301.44%, marking a year-over-year change of. This contributed to the annual value of -6,566.07% for FY2024, which is N/A change from last year.
  • Per Prime Medicine's latest filing, its EBITDA Margin stood at -4,125.63% for Q3 2025, which was up 12.52% from -4,716.23% recorded in Q2 2025.
  • Prime Medicine's 5-year EBITDA Margin high stood at -1,937.52% for Q4 2024, and its period low was -25,084.21% during Q3 2024.
  • In the last 2 years, Prime Medicine's EBITDA Margin had a median value of -4,420.93% in 2025 and averaged -7,865.00%.
  • Data for Prime Medicine's EBITDA Margin shows a peak YoY spiked of 2,095,858bps (in 2025) over the last 5 years.
  • Prime Medicine's EBITDA Margin (Quarterly) stood at -1,937.52% in 2024, then soared by 2,095,858bps to -4,125.63% in 2025.
  • Its last three reported values are -4,125.63% in Q3 2025, -4,716.23% for Q2 2025, and -3,569.88% during Q1 2025.